|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 655 15TH STREET, NW, #300 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 7053-12
|
||||||||
|
6. House ID# 315800000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Michael C. Carozza, Vice President Federal Government Affairs |
Date | 01/19/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H. Con. Res. 85, S. Con. Res. 13, House and Senate Budget Resolutions. Lobbied to ensure safety and access to prescription drugs.
H.R. 3326 (Defense Appropriations Act)/H.R. 3288 (Transportation/HUD Consolidated Appropriations Act)/H.J. Res. 64 (Continuing Resolution). Lobbied to ensure safety and access to prescription drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
|
Christopher |
Pernie |
Mr. |
|
|
Lane |
Penry |
Mrs. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages.
H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Pernie |
Mr. |
|
|
Lane |
Penry |
Mrs. |
|
|
Dick |
Thompson |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
NO BILL, Bisphenol A (BPA). Lobbied Members of Congress regarding BPA in containers.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs.
H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs.
H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs.
H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity.
S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs.
H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness.
H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.
S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs.
S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs.
H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs.
H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs.
H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs.
H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs.
H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs.
H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity.
H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
|
Christopher |
Pernie |
Mr. |
|
|
Lane |
Penry |
Mrs. |
|
|
Shawn |
Tarrant |
Mr. |
|
|
Dick |
Thompson |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D.
H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills.
S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations.
H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D.
H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills.
S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
|
Christopher |
Pernie |
Mr. |
|
|
Lane |
Penry |
Mrs. |
|
|
Shawn |
Tarrant |
Mr. |
|
|
Dick |
Thompson |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
|
Christopher |
Pernie |
Mr. |
|
|
Dick |
Thompson |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Future of Trade Agreements. Lobbied in support of the pending Columbian and Korean FTAs.
Implementation of discriminatory pricing decrees regarding Turkey. Lobbied against pricing decree.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Warr |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code WEL
16. Specific lobbying issues
NO BILL, WIC Program. Lobbied on reauthorization of WIC program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Carozza |
Mr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |